Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision | ||
| covid-19:treatments:monoclonal_antibodies [2022/01/13 22:36] brian | covid-19:treatments:monoclonal_antibodies [2022/01/13 23:55] (current) brian | ||
|---|---|---|---|
| Line 1: | Line 1: | ||
| - | ===== Monoclonal Antibodies ===== | + | ===== Anti-SARS-CoV-2 |
| - | + | Monoclonal antibodies, or mAbs, are made in a laboratory to fight a particular infection. The mAb treatment is usually offered at an infusion center because the treatment is given through an intravenous (IV) infusion or shots. | |
| [[sotrovimab]] \\ | [[sotrovimab]] \\ | ||
| Line 8: | Line 7: | ||
| [[Casirivimab]] plus [[imdevimab]] \\ | [[Casirivimab]] plus [[imdevimab]] \\ | ||
| + | The SARS-CoV-2 genome encodes 4 major structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N), as well as nonstructural and accessory proteins. The spike protein is further divided into 2 subunits, S1 and S2, that mediate host cell attachment and invasion. Through its receptor-binding domain (RBD), S1 attaches to angiotensin-converting enzyme 2 (ACE2) on the host cell; this initiates a conformational change in S2 that results in virus-host cell membrane fusion and viral entry. Often, anti-SARS-CoV-2 monoclonal antibodies (mAbs) target the spike protein. | ||